Management of patients with hematological cancers relies on genetic tests that inform diagnosis and prognosis, predict response to therapy, and measure minimal residual diseases. The detection of genetic aberrations in hematological malignancies with DNA fluorescence in situ hybridization (FISH) probe technology is a powerful means to prognosis and leads to a more efficient treatment of a wide range of cancers.
ASI uses a wide range of DNA fluorescence in situ hybridization (FISH) products from various vendors for the effective and rapid identification of genetic aberrations associated with hematopoietic disorders. Used as single probes, or in multi-color probe sets, these products are designed to identify various chromosome translocations, deletions, as well as other rearrangements associated with specific hematopoietic disorders. These probes can be applied to a variety of sample types prepared for metaphase or interphase analysis.
GenASIs SpotScan provides optimal solution for scanning hematological samples with the following unique features:
- Dramatic reduction in scanning time using an intelligent “pre-scan” to identify optimal regions of interest
- Detect, segment and classify touching nuclei accurately
- Sensitive camera and smart enhancement schemes to reveal the faintest and smallest signals
- Dedicated algorithms to address extreme fusion variabilities
GenASIs Applications are FDA cleared for the following GenASIs applications: BandView, FISHView, CEP XY, UroVysion, ALK & HER2/neu FISH and IHC Family for: HER2, ER, PR and Ki67. All other products are for research purposes only, not intended for diagnostic or therapeutic use.